Search by Drug Name or NDC
NDC 10019-0927-01 IFOSFAMIDE 1 g/20mL Details
IFOSFAMIDE 1 g/20mL
IFOSFAMIDE is a INTRAVENOUS INJECTION, POWDER, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Baxter Healthcare Corporation. The primary component is IFOSFAMIDE.
MedlinePlus Drug Summary
Ifosfamide is used in combination with other medications to treat cancer of the testicles that has not improved or that has worsened after treatment with other medications or radiation therapy. Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in your body.
Related Packages: 10019-0927-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ifosfamide Injection
Product Information
| NDC | 10019-0927 |
|---|---|
| Product ID | 10019-927_2a660f99-4a19-4ffe-9c54-b41f76ffff3f |
| Associated GPIs | 21101025002110 |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | IFOSFAMIDE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ifosfamide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, FOR SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 1 |
| Active Ingredient Units | g/20mL |
| Substance Name | IFOSFAMIDE |
| Labeler Name | Baxter Healthcare Corporation |
| Pharmaceutical Class | Alkylating Activity [MoA], Alkylating Drug [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA019763 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 10019-0927-01 (10019092701)
| NDC Package Code | 10019-927-01 |
|---|---|
| Billing NDC | 10019092701 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-927-01) / 20 mL in 1 VIAL, SINGLE-DOSE (10019-927-20) |
| Marketing Start Date | 2018-08-02 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |